Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection

Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezloto...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Med
Main Authors: Escudero-Sánchez, Rosa, Ruiz-Ruigómez, María, Fernández-Fradejas, Jorge, García Fernández, Sergio, Olmedo Samperio, María, Cano Yuste, Angela, Valencia Alijo, Angela, Díaz-Pollán, Beatriz, Rodríguez Hernández, María Jesús, Merino De Lucas, Esperanza, Martín Segarra, Oriol, Sáez Bejar, Carmen, Armiñanzas Castillo, Carlos, Gutiérrez-Gutiérrez, Belén, Rodríguez-Pardo, Dolors, Ramos-Martínez, Antonio, Torre-Cisneros, Julián, López-Medrano, Francisco, Cobo Reinoso, Javier
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7792623/
https://ncbi.nlm.nih.gov/pubmed/33374989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10010002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados